Recall Z-0094-2023

Siemens Healthcare Diagnostics Inc · initiated August 30, 2022

Class II Open, Classified

Class II – products that might cause a temporary health problem or pose a slight threat of a serious nature

Product

N Antiserum to Human IgG, 5mL Variant for BN II System and BN ProSpec System- IVD Siemens Material Number (SMN): 10446299

Codes / lots: UDI-DI: 0405686900179VF Lot Number: 153083; 153085; 153087A; 153090; 153095B; 153099A; 153004B. Future lots may be impacted by the issue but will then be provided with a corresponding instruction note within the reagent package

Reason for recall

N Antiserum to Human IgG are not meeting the current High-Dose Hook Effect expectation of up to 648 mg/L for IgGU (urine) and up to 2290 mg/L for IgGC (CSF).

FDA-determined cause: Under Investigation by firm

Action taken

Siemens Healthcare Diagnostics issued an Urgent Medical Device Correction (UMDC) PP-22-003-A-C US to US customers by FedEx on 08/30/2022; and Urgent Field Safety Notice (UFSN) PP-22-003-A-C OUS -all OUS Siemens reporting sites with affected customers, for distribution and regional reporting to their local competent authorities beginning on 08/19/2022. Letter states reason for recall, health risk and action to take: Please review this letter with your Medical Director. Discontinue use of N Antiserum to Human IgG lot 153095B for urine and CSF sample determination. However, the N Antiserum to Human IgG lot 153095B can still be used for serum sample determination. All other N Antiserum to Human IgG lots listed in Table 1 can continue to be used with the following new preliminary high dose hook thresholds for urine and CSF: " Urine: 395 mg/L " CSF: 412 mg/L Further information regarding establishment of the preliminary high dose hook threshold can be found within section Additional Information . " The specified high dose hook threshold for serum (83.3 g/L) remains unchanged for all N Antiserum to Human IgG lots. According to the IFU, in case of questionable results, the determinations should be repeated using the next higher sample dilution. For patient monitoring, consecutive immunoglobulin determinations should be performed from the same sample dilution, as far as possible. Review your inventory of the N Antiserum to Human IgG lot 153095B to determine your laboratory s replacement needs, if required, and to provide information to Siemens Healthineers for reporting to the authorities. Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days. Please retain this letter with your laboratory records and forward this letter to those who may have received this product. If you have any questions, please contact your Siemens Healthineers Customer Care Center or your local Siemens Healthineers technical support representative.

Details

Recall number
Z-0094-2023
Initiated
August 30, 2022
Posted by FDA
October 14, 2022
Product code
CFN – Method, Nephelometric, Immunoglobulins (G, A, M)
Quantity
10,201 packs
Distribution
Nationwide
Recalling firm
Siemens Healthcare Diagnostics Inc, Tarrytown

Official FDA recall record

Other products in the same recall event

RecallProductInitiated
Z-0093-2023 Class IIN Antiserum to Human IgG, 2mL Variant for BN II System and BN ProSpec System-IVD Siemens…N Antiserum to Human IgG are not meeting the current High-Dose Hook Effect expectation of up to 648 mg/L for… 08/30/2022Open, Classified